NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences insider filing: Chief Medical Officer Roberts Eiry holds 51k shares and long‑term RSUs/Options, signaling strong leadership confidence and potential dilution impact for investors.

Neurocrine Biosciences insider trades reveal disciplined liquidity management and steady executive holdings, signaling strong governance and growth prospects.

Neurocrine insiders buying PRSUs show strong pipeline confidence; with Phase‑2/3 trials and Fast‑Track approval, investors should watch trial data, regulatory moves, and earnings to gauge real value.

Neurocrine insider Eric Benevich buys 3,194 shares at $43.24—80% below market—showing confidence in a rising neuropsychiatric pipeline and bullish outlook.